Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Microcide, Daiichi Pharmaceutical deal

The companies will develop Pseudomonas aeruginosa efflux pump

Read the full 83 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE